Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Krystal Biotech, Inc. (NASDAQ: KRYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Krystal Biotech is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines such as VYJUVEK for dystrophic epidermolysis bullosa and a pipeline of investigational programs in respiratory, ophthalmology, dermatology, oncology, and aesthetics.
Through this page, users can review Form 8‑K current reports in which Krystal Biotech discloses material events. Recent 8‑K filings have covered quarterly financial results, commercial launches of VYJUVEK in new markets such as Japan, regulatory approvals, and key clinical milestones, including updates on trials for KB801 in neurotrophic keratitis and KB304 in aesthetics. These filings often incorporate press releases and slide presentations by reference, providing additional context on the company’s operational and clinical progress.
In addition to 8‑K reports, investors may use this page to navigate to Krystal Biotech’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which contain detailed information on its gene therapy platform, risk factors, financial statements, and segment information related to the development and commercialization of pharmaceutical products. For users interested in governance and compensation matters, proxy statements and related filings can also be accessed.
Stock Titan enhances these documents with AI-powered summaries that explain the key points of lengthy filings, helping readers quickly understand financial results, clinical updates, and regulatory developments without reading every page. Real-time integration with EDGAR ensures that new Krystal Biotech filings, including any future Forms 4 reporting insider transactions, 10‑Q, or 10‑K submissions, appear promptly, while AI-generated highlights point to sections that may be most relevant for KRYS shareholders and analysts.
On 30 June 2025, Krystal Biotech (KRYS) filed a Form 4 reporting that independent director Julian S. Gangolli received 5,000 stock options with an exercise price of $137.46 and a 10-year term expiring 30 June 2035. The award vests in 12 equal monthly tranches through June 2026, aligning the director’s incentives with shareholder value over the next year. No common shares were bought or sold, and the grant represents potential dilution of well under 0.1 % of outstanding shares, making it immaterial from a capitalization standpoint.
Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an equity compensation grant to director Daniel Janney on 30 June 2025.
- Type of security: Non-qualified stock option (right to buy common shares).
- Quantity: 5,000 options.
- Exercise price: $137.46 per share.
- Vesting schedule: Awards vest in equal monthly installments over 12 months beginning on the grant date.
- Expiration: 30 June 2035 (10-year term).
- Post-transaction beneficial ownership: 5,000 derivative securities reported as directly held; no change in non-derivative share ownership was reported.
The filing represents a routine director compensation grant. The size—5,000 options—equates to a low single-digit percentage of average daily trading volume and an immaterial fraction of KRYS’s ~25 million shares outstanding, implying limited dilution or market impact. No open-market purchases or sales were reported.
FAQ
What is the current stock price of Krystal Biotech (KRYS)?
What is the market cap of Krystal Biotech (KRYS)?
